Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022;40(6):745-753.
doi: 10.1159/000521768. Epub 2022 Jan 5.

Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Khin Naing Thin  1   2 , Andrew Tran  1   3 , Jie Li  4   5 , Eunice Yewon Lee  1 , Hongli Yang  6 , Fajuan Rui  6   7 , Chuanli Liu  6   7 , Christopher D Stave  8 , Ramsey C Cheung  1   9 , Mindie H Nguyen  1   10
Affiliations
Meta-Analysis

Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Khin Naing Thin et al. Dig Dis. 2022.

Abstract

Introduction: Chronic hepatitis B (CHB) patients with metabolic syndrome (MetS) may present increased risk of liver-related outcomes (LROs), but prior studies were limited by small sample size and/or conflicting results. Using a systematic review and meta-analytic approach, we aimed to determine the association between MetS and LROs in CHB.

Methods: Two researchers independently screened studies from the PubMed, Embase, Web of Science, and Cochrane Library databases from inception to January 21, 2020, and extracted the data. Estimates were pooled using a random-effects model.

Results: We screened 2,228 articles and included 10 eligible studies (18,360 CHB patients, 2,557 with MetS). MetS was significantly associated with LROs overall (odds ratio = 2.45, 95% confidence interval = 1.39-4.32) but not the individual LRO components but subgroup analyses were limited by small study numbers.

Discussion/conclusion: MetS is associated with almost 3-folds higher risk of LROs in CHB and should be considered in management decisions. However, additional studies are needed.

Keywords: Diabetes; Hepatocellular carcinoma; Liver fibrosis; Mortality; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Mindie Nguyen has served as a consultant or in advisory board for Spring Bank, Novartis, Gilead, Intercept, Exact Sciences, Laboratory of Advanced Medicine, Eisai, and Bayer and has received grant/research support from Gilead, Pfizer, Enanta, Vir, National Cancer Institute, B. K. Kee Foundation, and Glycotest. All others: none to declare.

Figures

Fig. 1
Fig. 1
Systematic literature search and screening for outcomes of CHB in patients with MetS.
Fig. 2
Fig. 2
Forest plot for association of HBV patients with MetS and LROs.
Fig. 3
Fig. 3
Forest plot for subgroup analysis.
See this image and copyright information in PMC

References

    1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386((10003)):1546–1555. - PubMed
    1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003 Dec;362((9401)):2089–2094. - PubMed
    1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(Suppl 1):3–8. - PubMed
    1. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381((9865)):468–475. - PubMed
    1. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135((1)):111–121. - PubMed

MeSH terms